Short-term Efficacy Of Low Dose Urokinase Thrombolysis Combined With Anticoagulation In The Treatment Of Non-high-risk Pulmonary Embolism With Venous Thrombosis Of Lower Extremity

Objectives Patients with non-high risk pulmonary embolism complicated with venous thrombosis of lower extremity were treated with simple anticoagulant therapy and low dose urokinase thrombolytic therapy.The thrombolysis and bleeding of CTPA and lower extremity CTV were compared before and after treatment.To evaluate the effect of clinical treatment.Methods The patients diagnosed with acute pulmonary embolism at Tangshan Workers' Hospital from February 2013 to July 2017 were selected and 86 non-high-risk patients with venous thromboembolism of the lower extremities were selected according to the severity index of pulmonary embolism.According to different treatment methods,57 cases were included in the control group,including 24 males and 33 females.The experimental group consisted of 29 patients,including 18 males and 11 females.The patients were compared with non-high-risk pulmonary embolism patients with venous thrombosis of the lower extremities.Simple anticoagulant,low-dose urokinase thrombolysis + anticoagulant before treatment and 7-10 days after treatment CTPA and lower extremity CTV thrombolysis,dyspnea,cough,chest pain,swelling and pain of affected limbs,and bleeding and other adverse reactions To evaluate the efficacy of these two different treatment options.Results After 7-10 days of treatment,the CTV thrombolysis in the affected limbs and the relief of pain and swelling of the affected limbs were significantly different between the two groups,with statistical significance(P<0.05).There were no statistically significant differences in the CTPA thrombolysis,dyspnea,cough,chest pain relief,and bleeding between the two groups(P>0.05).Conclusions Small dose urokinase and anticoagulant therapy for patients with non high risk pulmonary embolism with deep venous thrombosis and anticoagulant therapy can more effectively dissolve lower extremity venous thrombosis and relieve the symptoms of swelling and pain of the patients,reduce the source of emboli fundamentally,reduce the chance of recurrence of pulmonary embolism and improve the quality of life of the patients.No obvious advantages were found in dissolving pulmonary thrombus,relieving dyspnea,cough and chest pain,and did not increase adverse reactions such as bleeding.